These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 27084416)

  • 1. After Amarin v FDA: What Will the Future Hold for Off-label Promotion Regulation?
    Mackey TK; Liang BA
    Mayo Clin Proc; 2016 Jun; 91(6):701-6. PubMed ID: 27084416
    [No Abstract]   [Full Text] [Related]  

  • 2. Origins of the prohibition against off-label promotion.
    Coleman TS
    Food Drug Law J; 2014; 69(2):161-236, i. PubMed ID: 25163210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Off-label promotion: government theories of prosecution and facts that drive them.
    Burroughs AD; Levy MC; Schwab GG; Paik Y
    Food Drug Law J; 2010; 65(3):555-88. PubMed ID: 24479242
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA regulation of off-label drug promotion under attack.
    Kesselheim AS; Mello MM; Avorn J
    JAMA; 2013 Feb; 309(5):445-6. PubMed ID: 23385267
    [No Abstract]   [Full Text] [Related]  

  • 5. Off-label drug use and promotion: balancing public health goals and commercial speech.
    Kesselheim AS
    Am J Law Med; 2011; 37(2-3):225-57. PubMed ID: 21847880
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluating promotional claims as false or misleading.
    Brushwood DB; Knox CA; Liu W; Jenkins KA
    Am J Health Syst Pharm; 2013 Nov; 70(21):1941-4. PubMed ID: 24128969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. United States v. Caronia: Off-Label Drug Promotion and First Amendment Balancing.
    Rabinowitz DP
    Fordham Law Rev; 2018 Apr; 86(5):2595-623. PubMed ID: 29993225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug labeling and promotion: evolution and application of regulatory policy.
    Hayes TA
    Food Drug Law J; 1996; 51(1):57-73. PubMed ID: 11794353
    [No Abstract]   [Full Text] [Related]  

  • 10. When true enough is not good enough.
    Nat Med; 2013 Jan; 19(1):1. PubMed ID: 23295988
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
    [No Abstract]   [Full Text] [Related]  

  • 12. Manufacturers' promotion of off-label drug use: implications for drug safety.
    Zieve A; Carome MA
    Expert Opin Drug Saf; 2016 Sep; 15(9):1149-51. PubMed ID: 27145440
    [No Abstract]   [Full Text] [Related]  

  • 13. An unhealthy disregard.
    Nat Med; 2010 Jun; 16(6):609. PubMed ID: 20526289
    [No Abstract]   [Full Text] [Related]  

  • 14. Promotion of Drugs for Off-label Uses: The US Food and Drug Administration at a Crossroads.
    Kim J; Kapczynski A
    JAMA Intern Med; 2017 Feb; 177(2):157-158. PubMed ID: 27820607
    [No Abstract]   [Full Text] [Related]  

  • 15. To inform or persuade? Direct-to-consumer advertising of prescription drugs.
    Berndt ER
    N Engl J Med; 2005 Jan; 352(4):325-8. PubMed ID: 15673797
    [No Abstract]   [Full Text] [Related]  

  • 16. Hidden truth: The perils and protection of off-label drug and medical device promotion.
    Conko G
    Health Matrix Clevel; 2011; 21(1):149-87. PubMed ID: 21847900
    [No Abstract]   [Full Text] [Related]  

  • 17. Off-label prescription advertising, the FDA and the First Amendment: a study in the values of commercial speech protection.
    Klasmeier C; Redish MH
    Am J Law Med; 2011; 37(2-3):315-57. PubMed ID: 21847884
    [No Abstract]   [Full Text] [Related]  

  • 18. Regulating off-label promotion of medications: has the pendulum swung too far?
    Hoffman MB; Yentzer BA; Feldman SR
    Skin Therapy Lett; 2015; 20(3):1-4. PubMed ID: 26382556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bias at the gate?: The pharmaceutical industry's influence on the federally approved drug compendia.
    Gabrielsen L
    Am J Law Med; 2014; 40(1):141-63. PubMed ID: 24844045
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmaceuticals and medical devices: FDA oversight.
    Berry MD
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.